Eyegene, Inc. engages in the provision of research and development of pharmaceutical products. Its products include curing technologies and vaccines for diabetic retinopathy, decubitus ulcer, cervical cancer, and adjuvant immunotherapy. The company was founded on June 23, 2000 and is headquartered in Uiwang-si, South Korea.